Goldman Sachs Group Inc 9 Meters Biopharma, Inc. Transaction History

Goldman Sachs Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 May 14, 2024	SELL	$0.21 - $0.32 $981 - $1,496	-4,676 Reduced 5.77%	76,338 $16,000
Q3 2022 Nov 10, 2022	SELL	$0.21 - $0.32 $981 - $1,496	-4,676 Reduced 5.77%	76,338 $0
Q2 2022 May 14, 2024	BUY	$0.26 - $0.64 $21,063 - $51,848	81,014 New	81,014 $21,000
Q2 2022 Aug 15, 2022	BUY	$0.26 - $0.64 $228 - $563	880 Added 1.1%	81,014 $21,000
Q1 2022 May 16, 2022	SELL	$0.52 - $1.0 $23,324 - $44,854	-44,854 Reduced 35.89%	80,134 $48,000
Q4 2021 Feb 14, 2022	SELL	$0.85 - $1.33 $11,874 - $18,580	-13,970 Reduced 10.05%	124,988 $122,000
Q3 2021 Nov 10, 2021	BUY	$1.03 - $1.41 $143,126 - $195,930	138,958 New	138,958 $181,000

67.9K

Ticker NMTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,955,400
Market Cap $259K
Description
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as we...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.